Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study

References

• Austin J. Schizophrenia: an update and review. J Genet Couns 2005;14:329-40
   PubMedGoogle Scholar
• Li N, Chen G, Du W, et al. Population-level prevalence estimate and characteristic of psychiatric disability among Chinese adults. J Psychiatr Res 2011;45:1530-4
   PubMed Web of Science ®Google Scholar
• Stip E. Cognitive, schizophrenia and the effect of antipsychotics. Encephale 2006;32:341-50
   PubMed Web of Science ®Google Scholar
• Sharif ZA. Overview of safety and tolerability of atypical antipsychotics used in primary care. Primary Care Companion J Clin Psychiatry 2003;5(Suppl 3):14-21
   Google Scholar
• Leuchet S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-anaysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. DRUGS 2011;71:179-208
   PubMed Web of Science ®Google Scholar
• Thomas SP, Nandhra HS, Singh SP. Pharmacologic treatment of first-episode schizophrenia: a review of the literature. Prim Care Companion CNS Disord 2012;14:PCC.11r01198
   PubMedGoogle Scholar
• Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61
   PubMed Web of Science ®Google Scholar
• Cheer SM, Wagstaff AJ. Quetiapine a review of its use in the management of schizophrenia. CNS Drugs 2004;18:173-99
   PubMed Web of Science ®Google Scholar
• Liorca PM. Second generation antipsychotics in bipolar depression: a new therapeutic options? Encephale 2011;37(Suppl 3):S209-13
   PubMed Web of Science ®Google Scholar
• Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012;27:76-90
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000;68:29-39
   PubMed Web of Science ®Google Scholar
• Choi MJ, Lee HJ, Lee HJ, et al. Association between major depressive disorder and the −1438A/G polymorphism of the serotonin 2A receptor gene. Neuropsychobiology 2004;49:38-41
   PubMed Web of Science ®Google Scholar
• Zhomitsky S, Potvin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorder: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 2011;26:183-92
   PubMed Web of Science ®Google Scholar
• Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004;20:619-26
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang G, Cai Z, et al. Effectiveness and safety of monotherapy quetiapine in acute schizophrenia. Shanghai Arch Psychiatry 2010;22(5):291-294
   Google Scholar
• Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders: medication selection, dosing, and dose equivalence. J Clin Psychiatry 2003;64(Suppl 12):12-51
   Google Scholar
• Lieberman J, McEvoy JP, Perkins D, et al. Comparison of atypical in first-episode: a randomized, 52-week comparison of olanzapine, quetiapine and rispridone. Eur Neuropsychopharmacol 2005;15(Suppl 3):S525.
   PubMedGoogle Scholar
• Reidel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2005;255:432-7
   PubMed Web of Science ®Google Scholar
• Knegtering R, Castelein S, Bous H, et al. A randomized, open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24:56-61
   PubMed Web of Science ®Google Scholar
• Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002;63(Suppl 13):32-8
   PubMedGoogle Scholar
• Fan ZG. Efficacy of quetiapine in treatment of schizophrenia with depressive symptoms. Chin J New Drugs Clin Rem 2004;23:884-6
   Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60
   PubMed Web of Science ®Google Scholar
• Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012;26:435-60
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2000;63:1156-63
   Web of Science ®Google Scholar
• Mclntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-19
   PubMed Web of Science ®Google Scholar
• Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006;67:1093-103
   PubMed Web of Science ®Google Scholar
• Perez V, Canas F, Tafalla M; TESIS Study Group. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. Int Clin Psychopharmacol 2008;23:138-49
   PubMed Web of Science ®Google Scholar
• Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008;18(Suppl 2):S108-14
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-9
   PubMed Web of Science ®Google Scholar
• Goldstein JM. Mechanism of action of quetiapine: a modulator of dopamine at the D2 receptor. Presented at the 43rd annual meeting of the American College of Neuropsychopharmacology, 12–16 December 2004, San Juan, Puerto Rico
   Google Scholar
• Smith AM, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005;25:331-5
   PubMed Web of Science ®Google Scholar